Bio-Rad Laboratories (BIO-B) Operating Leases (2019 - 2026)

Bio-Rad Laboratories (BIO-B) has 8 years of Operating Leases data on file, last reported at $138.6 million in Q1 2026.

• Quarterly Operating Leases fell 17.3% year-over-year to $138.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $138.6 million (down 17.3% YoY) and the FY2025 annual result came in at $145.7 million, up 10.88% from the prior year.
• Operating Leases eased to $138.6 million in Q1 2026 per BIO-B's latest filing, from $145.7 million in the prior quarter.
• Across five years, Operating Leases topped out at $206.3 million in Q3 2023 and bottomed at $131.4 million in Q4 2024.
• The 5-year median for Operating Leases is $183.1 million (2023), against an average of $173.8 million.
• The widest annual swing landed in 2023, when Operating Leases soared 40.15%; it then slumped 30.24% in 2024.
• Tracing BIO-B's Operating Leases over 5 years: stood at $189.9 million in 2022, then retreated by 12.85% to $165.5 million in 2023, then retreated by 20.6% to $131.4 million in 2024, then advanced by 10.88% to $145.7 million in 2025, then slipped by 4.87% to $138.6 million in 2026.
• Per Business Quant, the three latest BIO-B Operating Leases figures stand at $138.6 million (Q1 2026), $145.7 million (Q4 2025), and $192.6 million (Q3 2025).

Peer Comparison